Shots:
- BBOT will reverse merge with Helix in a SPAC transaction, where combined entity – “BBOT” will be listed on Nasdaq; closing expected in Q3’25
- Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity’s implied pro forma equity value is ~$949M, with BBOT shareholders rolling 100% of their equity
- Combined entity will develop BBO-8520 in the P-I (ONKORAS-101) trial for KRAS^G12C mutant NSCLC, BBO-10203 in the P-I (BREAKER-101) trial for HER2+ & HR+/HER2- breast cancer, KRAS mCRC, & KRAS mutant NSCLC, as well as BBO-11818, with first pts dosing in H1’25
Ref: BridgeBio Oncology Therapeutics | Image: BridgeBio Oncology Therapeutics
Related News:- The US FDA Grants Fast Track Designation to BridgeBio Oncology Therapeutics’ BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
